Pliant Therapeutics 株価情報 (NASDAQ: PLRX)

Pliant Therapeutics (NASDAQ:PLRX) 株価情報

Pliant Therapeutics

Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.

Pliant Therapeutics Inc

CoStar Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSGP#NASDAQ">CSGP</a>) has outperformed the market over the past 10 years by 5.42% on an annualized basis producing an average annual return of 14.98%. Currently, CoStar Group has a market capitalization of $34.11 billion. 
Buying $100 In CSGP: If an investor had bought $100 of CSGP stock 10 years ago, it would be worth $404.13 today based on a price of $80.87 for CSGP at the time of writing.
<h3>CoStar Group's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745360114_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

CSGP

If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today

Timberland Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSBK#NASDAQ">TSBK</a>) reported quarterly earnings of $0.85 per share. This is a 21.43 percent increase over earnings of $0.70 per share from the same period last year.

Earnings

TSBK

Timberland Bancorp Q2 EPS $0.85 Up From $0.70 YoY

Throughout the last three months, 5 analysts have evaluated Extreme Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXTR#NASDAQ">EXTR</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $19.6, a high estimate of $22.00, and a low estimate of $16.00. Experiencing a 2.0% decline, the current average is now lower than the previous average price target of $20.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1745359270_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Extreme Networks. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Mike Genovese &#x7C;Rosenblatt &#x7C;Lowers &#x7C;Buy &#x7C; $18.00&#x7C;$22.00 &#x7C; 
&#x7C;Mike Genovese &#x7C;Rosenblatt &#x7C;Maintains &#x7C;Buy &#x7C; $22.00&#x7C;$22.00 &#x7C; 
&#x7C;Eric Martinuzzi &#x7C;Lake Street &#x7C;Raises &#x7C;Hold &#x7C; $16.00&#x7C;$15.00 &#x7C; 
&#x7C;Mike Genovese &#x7C;Rosenblatt &#x7C;Raises &#x7C;Buy &#x7C; $22.00&#x7C;$21.00 &#x7C; 
&#x7C;Ryan Koontz &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $20.00&#x7C;$20.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Extreme Networks. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Extreme Networks compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Extreme Networks's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Extreme Networks's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EXTR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Extreme Networks analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Extreme Networks</h2>
Extreme Networks Inc provides cloud networking solutions and industry services and support. Extreme designs, develops, and manufactures wired, wireless, and software-defined wide area-network (SD- WAN) infrastructure equipment, software and cloud-based network management solutions. The company's cloud solution is a single platform that offers unified network management of wireless access points, switches, and SD-WAN. The company operates in a single segment which develops and markets network infrastructure equipment. Roughly half of the firm's revenue is generated in the Americas, with the rest coming from Europe, the Middle East, Africa, and Asia-Pacific.
<h3>A Deep Dive into Extreme Networks's Financials</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Extreme Networks's revenue growth over a period of 3M has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -5.74%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: Extreme Networks's net margin is impressive, surpassing industry averages. With a net margin of 2.64%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Extreme Networks's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 17.59%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.69%, the company showcases effective utilization of assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 4.52, caution is advised due to increased financial risk.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

EXTR

5 Analysts Assess Extreme Networks: What You Need To Know

7 analysts have shared their evaluations of Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $58.71, a high estimate of $65.00, and a low estimate of $54.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 1.16%. 
<img src="https://www.benzinga.com/files/images/story/2025/1745359260_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Bristol-Myers Squibb. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;David Amsellem &#x7C;Piper Sandler &#x7C;Announces &#x7C;Overweight &#x7C; $65.00&#x7C;- &#x7C; 
&#x7C;Carter Gould &#x7C;Cantor Fitzgerald &#x7C;Announces &#x7C;Neutral &#x7C; $55.00&#x7C;- &#x7C; 
&#x7C;Trung Huynh &#x7C;UBS &#x7C;Lowers &#x7C;Neutral &#x7C; $54.00&#x7C;$60.00 &#x7C; 
&#x7C;Asad Haider &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Neutral &#x7C; $55.00&#x7C;$67.00 &#x7C; 
&#x7C;Mohit Bansal &#x7C;Wells Fargo &#x7C;Raises &#x7C;Equal-Weight &#x7C; $62.00&#x7C;$60.00 &#x7C; 
&#x7C;Olivia Brayer &#x7C;Cantor Fitzgerald &#x7C;Raises &#x7C;Neutral &#x7C; $55.00&#x7C;$50.00 &#x7C; 
&#x7C;Andrew Baum &#x7C;Citigroup &#x7C;Raises &#x7C;Neutral &#x7C; $65.00&#x7C;$60.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Bristol-Myers Squibb. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Bristol-Myers Squibb compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Bristol-Myers Squibb's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Bristol-Myers Squibb's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/BMY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Bristol-Myers Squibb analyst ratings.</a>
<h2>Unveiling the Story Behind Bristol-Myers Squibb</h2>
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
<h3>Bristol-Myers Squibb's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Bristol-Myers Squibb's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 7.54%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Bristol-Myers Squibb's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 0.58%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Bristol-Myers Squibb's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 0.43%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Bristol-Myers Squibb's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.08%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Bristol-Myers Squibb's debt-to-equity ratio is notably higher than the industry average. With a ratio of 3.13, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 7 Analysts Discuss Bristol-Myers Squibb Stock

11 analysts have shared their evaluations of Analog Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $250.73, along with a high estimate of $300.00 and a low estimate of $170.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 0.62%. 
<img src="https://www.benzinga.com/files/images/story/2025/1745359250_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A clear picture of Analog Devices's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Tom O'Malley &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $170.00&#x7C;$240.00 &#x7C; 
&#x7C;Tore Svanberg &#x7C;Stifel &#x7C;Lowers &#x7C;Buy &#x7C; $225.00&#x7C;$275.00 &#x7C; 
&#x7C;Christopher Danely &#x7C;Citigroup &#x7C;Lowers &#x7C;Buy &#x7C; $235.00&#x7C;$265.00 &#x7C; 
&#x7C;Rick Schafer &#x7C;Oppenheimer &#x7C;Raises &#x7C;Outperform &#x7C; $270.00&#x7C;$245.00 &#x7C; 
&#x7C;William Stein &#x7C;Truist Securities &#x7C;Raises &#x7C;Hold &#x7C; $248.00&#x7C;$230.00 &#x7C; 
&#x7C;Harlan Sur &#x7C;JP Morgan &#x7C;Raises &#x7C;Overweight &#x7C; $300.00&#x7C;$280.00 &#x7C; 
&#x7C;Timothy Arcuri &#x7C;UBS &#x7C;Raises &#x7C;Buy &#x7C; $300.00&#x7C;$275.00 &#x7C; 
&#x7C;Joe Quatrochi &#x7C;Wells Fargo &#x7C;Raises &#x7C;Equal-Weight &#x7C; $240.00&#x7C;$220.00 &#x7C; 
&#x7C;Joseph Moore &#x7C;Morgan Stanley &#x7C;Raises &#x7C;Overweight &#x7C; $250.00&#x7C;$248.00 &#x7C; 
&#x7C;David Williams &#x7C;Benchmark &#x7C;Raises &#x7C;Buy &#x7C; $275.00&#x7C;$245.00 &#x7C; 
&#x7C;David Williams &#x7C;Benchmark &#x7C;Announces &#x7C;Buy &#x7C; $245.00&#x7C;- &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Analog Devices. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Analog Devices compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Analog Devices's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Analog Devices's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ADI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Analog Devices analyst ratings.</a>
<h2>Discovering Analog Devices: A Closer Look</h2>
Analog Devices is a leading analog, mixed-signal, and digital-signal processing chipmaker. The firm has a significant market share lead in converter chips, which are used to translate analog signals to digital and vice versa. The company serves tens of thousands of customers; more than half of its chip sales are to industrial and automotive end markets. ADI's chips are also incorporated into wireless infrastructure equipment.
<h3>Understanding the Numbers: Analog Devices's Finances</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3M period, Analog Devices faced challenges, resulting in a decline of approximately -3.56% in revenue growth as of 31 January, 2025. This signifies a reduction in the company's top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Analog Devices's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 16.15%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Analog Devices's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 1.11%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.81%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Analog Devices's debt-to-equity ratio is below the industry average. With a ratio of 0.22, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Analog Devices Stock: Analyst Perspectives (11 Ratings)

In the preceding three months, 14 analysts have released ratings for Boyd Gaming (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYD#NYSE">BYD</a>), presenting a wide array of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Boyd Gaming, revealing an average target of $79.71, a high estimate of $88.00, and a low estimate of $72.00. Marking an increase of 2.28%, the current average surpasses the previous average price target of $77.93. 
<img src="https://www.benzinga.com/files/images/story/2025/1745359240_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Boyd Gaming among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Brandt Montour &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $73.00&#x7C;$78.00 &#x7C; 
&#x7C;Stephen Grambling &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $72.00&#x7C;$75.00 &#x7C; 
&#x7C;Joseph Stauff &#x7C;Susquehanna &#x7C;Lowers &#x7C;Positive &#x7C; $75.00&#x7C;$77.00 &#x7C; 
&#x7C;Barry Jonas &#x7C;Truist Securities &#x7C;Lowers &#x7C;Buy &#x7C; $85.00&#x7C;$92.00 &#x7C; 
&#x7C;Joseph Stauff &#x7C;Susquehanna &#x7C;Lowers &#x7C;Positive &#x7C; $77.00&#x7C;$79.00 &#x7C; 
&#x7C;Stephen Grambling &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $81.00&#x7C;$82.00 &#x7C; 
&#x7C;Brandt Montour &#x7C;Barclays &#x7C;Raises &#x7C;Equal-Weight &#x7C; $78.00&#x7C;$74.00 &#x7C; 
&#x7C;Steven Wieczynski &#x7C;Stifel &#x7C;Raises &#x7C;Hold &#x7C; $82.00&#x7C;$74.00 &#x7C; 
&#x7C;Daniel Politzer &#x7C;Wells Fargo &#x7C;Raises &#x7C;Overweight &#x7C; $88.00&#x7C;$82.00 &#x7C; 
&#x7C;Ben Chaiken &#x7C;Mizuho &#x7C;Raises &#x7C;Outperform &#x7C; $86.00&#x7C;$79.00 &#x7C; 
&#x7C;Barry Jonas &#x7C;Truist Securities &#x7C;Raises &#x7C;Buy &#x7C; $88.00&#x7C;$85.00 &#x7C; 
&#x7C;Joseph Stauff &#x7C;Susquehanna &#x7C;Raises &#x7C;Neutral &#x7C; $77.00&#x7C;$69.00 &#x7C; 
&#x7C;Joseph Greff &#x7C;JP Morgan &#x7C;Raises &#x7C;Neutral &#x7C; $80.00&#x7C;$74.00 &#x7C; 
&#x7C;Brandt Montour &#x7C;Barclays &#x7C;Raises &#x7C;Equal-Weight &#x7C; $74.00&#x7C;$71.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Boyd Gaming. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Boyd Gaming compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Boyd Gaming's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Boyd Gaming's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/BYD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Boyd Gaming analyst ratings.</a>
<h2>Discovering Boyd Gaming: A Closer Look</h2>
Boyd Gaming Corp is a multi-jurisdictional gaming company. The company operates wholly-owned gaming entertainment properties (casino space, slot machines, table games, and hotel rooms) in Nevada, Illinois, Indiana, Iowa, Kansas, Louisiana, Mississippi, Missouri, Ohio, and Pennsylvania. Geographical regions separate its business segments: Las Vegas Locals, Downtown Las Vegas, Midwest and South, and Online. Midwest and South hold the key number of entertainment properties, and it generate the majority of sales for the company.
<h3>Boyd Gaming: A Financial Overview</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Over the 3M period, Boyd Gaming showcased positive performance, achieving a revenue growth rate of 9.06% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 16.38%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Boyd Gaming's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 10.61%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Boyd Gaming's ROA stands out, surpassing industry averages. With an impressive ROA of 2.69%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Boyd Gaming's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 2.49.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Boyd Gaming: Insights From 14 Analyst Reviews

14 analysts have shared their evaluations of Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $190.21, with a high estimate of $265.00 and a low estimate of $135.00. Highlighting a 9.82% decrease, the current average has fallen from the previous average price target of $210.93. 
<img src="https://www.benzinga.com/files/images/story/2025/1745359228_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A comprehensive examination of how financial experts perceive Biogen is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Brian Abrahams &#x7C;RBC Capital &#x7C;Raises &#x7C;Outperform &#x7C; $225.00&#x7C;$221.00 &#x7C; 
&#x7C;Matthew Harrison &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $152.00&#x7C;$157.00 &#x7C; 
&#x7C;Christopher Raymond &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Neutral &#x7C; $135.00&#x7C;$138.00 &#x7C; 
&#x7C;George Farmer &#x7C;Scotiabank &#x7C;Lowers &#x7C;Sector Outperform&#x7C; $224.00&#x7C;$244.00 &#x7C; 
&#x7C;Evan Seigerman &#x7C;BMO Capital &#x7C;Lowers &#x7C;Market Perform &#x7C; $139.00&#x7C;$156.00 &#x7C; 
&#x7C;Matthew Harrison &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $157.00&#x7C;$192.00 &#x7C; 
&#x7C;Salveen Richter &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Buy &#x7C; $245.00&#x7C;$281.00 &#x7C; 
&#x7C;Brian Abrahams &#x7C;RBC Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $225.00&#x7C;$231.00 &#x7C; 
&#x7C;Geoff Meacham &#x7C;Citigroup &#x7C;Lowers &#x7C;Neutral &#x7C; $145.00&#x7C;$160.00 &#x7C; 
&#x7C;Mohit Bansal &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $140.00&#x7C;$165.00 &#x7C; 
&#x7C;Andrew Fein &#x7C;HC Wainwright &amp; Co. &#x7C;Lowers &#x7C;Buy &#x7C; $241.00&#x7C;$300.00 &#x7C; 
&#x7C;Srikripa Devarakonda&#x7C;Truist Securities &#x7C;Lowers &#x7C;Buy &#x7C; $210.00&#x7C;$220.00 &#x7C; 
&#x7C;Sumant Kulkarni &#x7C;Canaccord Genuity &#x7C;Lowers &#x7C;Buy &#x7C; $265.00&#x7C;$298.00 &#x7C; 
&#x7C;Geoff Meacham &#x7C;Citigroup &#x7C;Lowers &#x7C;Neutral &#x7C; $160.00&#x7C;$190.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Biogen. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Biogen compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Biogen's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Biogen's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/BIIB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Biogen analyst ratings.</a>
<h2>Get to Know Biogen Better</h2>
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
<h3>A Deep Dive into Biogen's Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Biogen's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 2.87%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Biogen's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 10.86%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Biogen's ROE stands out, surpassing industry averages. With an impressive ROE of 1.61%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.95%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.4.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BIIB

14 Analysts Have This To Say About Biogen

4 analysts have shared their evaluations of Bank of Hawaii (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOH#NYSE">BOH</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $69.5, along with a high estimate of $79.00 and a low estimate of $64.00. Marking an increase of 2.58%, the current average surpasses the previous average price target of $67.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1745359218_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Bank of Hawaii. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Jared Shaw &#x7C;Barclays &#x7C;Raises &#x7C;Underweight &#x7C; $67.00&#x7C;$64.00 &#x7C; 
&#x7C;Jared Shaw &#x7C;Barclays &#x7C;Lowers &#x7C;Underweight &#x7C; $64.00&#x7C;$66.00 &#x7C; 
&#x7C;Jeff Rulis &#x7C;DA Davidson &#x7C;Raises &#x7C;Neutral &#x7C; $79.00&#x7C;$75.00 &#x7C; 
&#x7C;Andrew Liesch &#x7C;Piper Sandler &#x7C;Raises &#x7C;Underweight &#x7C; $68.00&#x7C;$66.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Bank of Hawaii. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Bank of Hawaii compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Bank of Hawaii's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Bank of Hawaii's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/BOH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Bank of Hawaii analyst ratings.</a>
<h2>Discovering Bank of Hawaii: A Closer Look</h2>
Bank of Hawaii Corp provides a broad range of financial products and services predominantly to customers in Hawaii, Guam, and other Pacific Islands. The Bank's subsidiaries are engaged in equipment leasing, securities brokerage, investment advisory services, and providing credit insurance. It is organized into three business segments for management reporting purposes: Consumer Banking, Commercial Banking, and Treasury and Other. Majority of the revenue is generated from Consumer Banking segment which offers a broad range of financial products and services, including loan, deposit and insurance products; private banking and international client banking services; trust services; investment management; and institutional investment advisory services.
<h3>Understanding the Numbers: Bank of Hawaii's Finances</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Over the 3M period, Bank of Hawaii showcased positive performance, achieving a revenue growth rate of 3.21% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.
Net Margin: Bank of Hawaii's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 20.99%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Bank of Hawaii's ROE stands out, surpassing industry averages. With an impressive ROE of 2.56%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Bank of Hawaii's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.14%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Bank of Hawaii's debt-to-equity ratio stands notably higher than the industry average, reaching 0.49. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: Simplified</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Bank of Hawaii Through The Eyes Of 4 Analysts

In the current market session, Equinor Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQNR#NYSE">EQNR</a>) price is at $23.40, after a 1.56% increase. However, over the past month, the stock decreased by 9.29%, and in the past year, by 14.24%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1745359216_0.png" alt="Past Year Chart" />

<h3>Evaluating Equinor P/E in Comparison to Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 30.41 in the Oil, Gas &amp; Consumable Fuels industry, Equinor Inc. has a lower P/E ratio of 7.41. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1745359216_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

EQNR

A Look Into Equinor Inc's Price Over Earnings

Wheaton Precious Metals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WPM#NYSE">WPM</a>) has outperformed the market over the past 5 years by 3.08% on an annualized basis producing an average annual return of 16.01%. Currently, Wheaton Precious Metals has a market capitalization of $37.43 billion. 
Buying $1000 In WPM: If an investor had bought $1000 of WPM stock 5 years ago, it would be worth $2,106.51 today based on a price of $82.50 for WPM at the time of writing.
<h3>Wheaton Precious Metals's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745359214_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Wheaton Precious Metals 5 Years Ago Would Be Worth This Much Today

WIIM

TSLA

Tesla shares are trading higher following Q1 financial results.

STLD

Steel Dynamics shares are trading higher after the company reported better-than-expected Q1 EPS and revenues.

Capital One shares are trading higher after the company reported better-than-expected Q1 adjusted EPS

General

Tesla CEO Musk Says Expects Time Allocation To DOGE To Drop Significantly In May; Says Next Month Will Be Devoting More Time To Tesla; Says Robotaxi Will Move Financial Needle Significantly By Middle To End Of Next Year

Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) has outperformed the market over the past 15 years by 10.59% on an annualized basis producing an average annual return of 21.0%. Currently, Insulet has a market capitalization of $17.14 billion. 
Buying $100 In PODD: If an investor had bought $100 of PODD stock 15 years ago, it would be worth $1,693.41 today based on a price of $244.02 for PODD at the time of writing.
<h3>Insulet's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745358317_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PODD

$100 Invested In Insulet 15 Years Ago Would Be Worth This Much Today

Nuveen Insured California Premium Fund Ii

Northann Corp Receives Notice Of Non-Compliance From NYSE American

Intuitive Surgical Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) reported first-quarter financial results Tuesday after the bell. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/04/g44936280/intuitive-announces-first-quarter-earnings">of the report</a>.
Q1 Earnings: Intuitive Surgical reported first-quarter revenue of $2.25 billion, beating analyst <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $2.19 billion, according to&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
The robotic-assisted surgery company reported first-quarter adjusted earnings of $1.81 per share, beating analyst estimates of $1.72 per share.
Total revenue was up 19% year-over-year as Worldwide da Vinci procedures increased approximately 17%. The company said it&nbsp;placed 367 da Vinci surgical systems in the quarter, versus 313 in the prior year&#8217;s quarter. Intuitive Surgical&#8217;s da Vinci surgical system installed base grew to 10,189 systems as of March 31, up 15% year-over-year.
Intuitive Surgical ended the quarter with $9.1 billion in cash, cash equivalents and investments, up $269 million from the fourth quarter. 
&#8220;Core measures of our business were healthy this quarter, and we are pleased by continued customer adoption of our platforms, including da Vinci 5. As we look ahead, we remain focused on enabling our customers to deliver on their goals: better patient outcomes, improved patient and care team experiences, lower total cost to treat, and increased access to care,&#8221; said&nbsp;Gary Guthart, CEO of Intuitive Surgical.
Guidance:&nbsp;Intuitive Surgical expects full-year 2025 worldwide da Vinci procedures to increase approximately&nbsp;15%&nbsp;to&nbsp;17%. The company expects gross profit margin to be between&nbsp;65%&nbsp;and&nbsp;66.5%&nbsp;of revenue in 2025, which includes an estimated 1.7% impact from tariffs. 
A conference call featuring additional commentary from executives started at 4:30 p.m. ET.
ISRG Price Action: <a href="http://benzinga.com/quote/isrg">Intuitive Surgical shares</a> were down 0.99% after-hours, trading at $474 at the time of publication Tuesday, per data from <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/04/44931246/regeneron-partners-with-japan-based-fujifilm-to-bolster-us-manufacturing-capacity-via-3-billion-deal">Regeneron Expands US Manufacturing With $3 Billion Fujifilm Deal</a></li>
</ul>
Photo: Shutterstock.

Guidance

Health Care

After-Hours Center

Movers

ISRG

Intuitive Surgical Shares Drop Following Q1 Earnings, Company Anticipates Profit Margin Impact From Tariffs

Visa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) has outperformed the market over the past 15 years by 8.92% on an annualized basis producing an average annual return of 19.33%. Currently, Visa has a market capitalization of $638.50 billion. 
Buying $100 In V: If an investor had bought $100 of V stock 15 years ago, it would be worth $1,426.14 today based on a price of $331.00 for V at the time of writing.
<h3>Visa's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745357413_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Visa 15 Years Ago Would Be Worth Today

SAP SE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAP#NYSE">SAP</a>) released its first-quarter results after Tuesday's closing bell. Here's a look at the key <a href="https://www.benzinga.com/pressreleases/25/04/n44936302/sap-quarterly-statement-q1-2025">figures from the report. </a>
The Details: SAP reported quarterly revenue of 9.01 billion euros ($9.48 billion), beating analyst estimates, according to Benzinga Pro. Earnings of 1.44 euros ($1.54) per share also came in ahead of estimates.
Read Next: <a href="https://www.benzinga.com/25/04/44935272/tesla-reports-q1-after-the-bell-68-expect-the-company-to-miss-analysts-estimates">Will Tesla Beat The Street? 68% Expect Something Markets May Not Be Ready For</a>&nbsp;
For the first quarter, SAP reported: 
<ul>
<li>Current cloud backlog of 18.2 billion euros, up 28% and up 29% at constant currencies.</li>
<li>Cloud revenue up 27% and up 26% at constant currencies.</li>
<li>Cloud&nbsp;ERP Suite revenue up 34% and up 33% at constant currencies.</li>
<li>Total revenue up 12% and up 11% at constant currencies.</li>
<li>IFRS operating profit of 2.3 billion euros; non-IFRS operating profit of 2.5 billion euros, up 60% and up 58% at constant currencies.</li>
</ul>
&#8220;Q1 once again underlines that our success formula is working. Current cloud backlog expanded 29% at constant currencies and total revenue saw a double-digit increase. With a share of more predictable revenue of 86%, SAP&#8217;s business model remains resilient in uncertain times,&#8221; said Christian Klein, CEO of SAP. 
&#8220;Our AI-powered portfolio enables companies to navigate supply chain disruptions in over 130 countries and to unlock efficiencies with agility and speed,&#8221; Klein added.
SAP Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, SAP stock was up 8.95% after-hours at $274.99 on Tuesday.  
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/25/04/44903087/amazon-stock-downgraded-price-target-slashed-as-tariffs-create-uncertainty">Amazon Stock Downgraded, Price Target Slashed As Tariffs Create Uncertainty&nbsp;</a></li>
</ul>
Photo: Shutterstock

Global

Tech

SAP Shares Climb On Better-Than-Expected Q1 Results

<a href="https://www.youtube.com/watch?v=AhesolYQqiA">https://www.youtube.com/watch?v=AhesolYQqiA</a>

Politics

Economics

President Trump Says Tariff On China Will Not Be As High As 145%; Says Crypto Needs Regulatory Certainty; Says Fed Should Lower Interest Rates; Says We Would Like Chair Be Early Or On Time; Says No Intention Of Firing FED Chair

Comments

Pliant Therapeutics

ニュース

パートナーシップ

ベンジンガ・グローバル